Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2019
MRD driven study. Addition of gemtuzumab to conventional chemotherapy to reduce MRD of patients with favorable/intermediate-risk AML. Post-consolidation assessment of MRD. Role of a post-SCT maintenance with glasdegib.
Epistemonikos ID: 605052fdd11485347c913514eb0e6bf4062cacb0
First added on: Jan 21, 2022